Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections. It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins. In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription factors critical to tumorigenesis. In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection. The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors. Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions. Copyright © 2015 The Authors. Published by Elsevier Ltd.
A., C., I., O., O., W., G., O., W., S., C., R., & R.J., P. (2015). HDAC8: A multifaceted target for therapeutic interventions. Trends in Pharmacological Sciences. M. Jung, Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universitat Freiburg, Freiburg, Germany. E-mail: email@example.com: Elsevier Ltd. Retrieved from http://www.elsevier.com/locate/tips